New insider activity at Daxor ( (DXR) ) has taken place on March 12, 2025.
CEO Michael Richard Feldschuh has made a significant investment in Daxor by purchasing 3,360 shares of the company’s stock, valued at $25,804.
Recent Updates on DXR stock
Daxor Corporation has recently reported significant developments, including a robust 116.5% year-on-year revenue growth and strategic acquisitions that are expected to be cash flow positive. The company has expanded its clinical partnerships and secured a $2.5 million contract from the Department of Defense, alongside additional NIH grants. Despite a delay in FDA approval for its next-generation analyzer, Daxor is poised for continued growth with plans for a 2025 product launch. The company’s financial strength is further demonstrated by an increase in net asset value per share from $7.08 to $7.25. These developments reflect Daxor’s strategic focus on expanding its presence in the healthcare sector and enhancing its technological offerings.
More about Daxor
YTD Price Performance: 2.65%
Average Trading Volume: 6,669
Technical Sentiment Consensus Rating: Buy